Evidence map›Paper›PMID 39115551›Full record

ArticleRheumatology international2024

Neuropsychiatric involvement in systemic lupus erythematosus contributes to organ damage beyond the nervous system: a post-hoc analysis of 5 phase III randomized clinical trials.

Dionysis Nikolopoulos, Nursen Cetrez, Julius Lindblom, Ioannis Parodis

Abstract read
In one paragraph

Article in Rheumatology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Dionysis NikolopoulosDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. dionysis.nikolopoulos@ki.se.ORCID 0000-0002-9894-6966
Nursen CetrezDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-9874-841X
Julius LindblomDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-1582-9471
Ioannis ParodisDivision of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-4875-5395

Funding

Nyckelfonden OLL-974804Reumatikerförbundet 2024 R-995557Stiftelsen Konung Gustaf V:s 80-årsfond FAI-2020-0741Stiftelsen Konung Gustaf V:s 80-årsfond FAI-2023-1006Stiftelsen Professor Nanna Svartz Fond 2021-00436Svenska Läkaresällskapet SLS-974449Ulla och Gustaf af Ugglas Stiftelse 2023-025029
6 · The paper itself

Abstract

objectiveTo investigate the association between neuropsychiatric systemic lupus erythematosus (NPSLE) and SLICC/ACR damage index (SDI) items, especially non-neuropsychiatric items.

methodsBaseline data from five phase III trials (BLISS-52, BLISS-76, BLISS-SC, BLISS-NEA, EMBRACE) were analysed. NPSLE involvement was defined as NP BILAG A/B/C/D (n = 272); NP BILAG E denoted non-neuropsychiatric SLE (n = 3273). We employed multivariable logistic regression analysis adjusting for age, sex, disease duration, and ethnicity.

resultsThe median (IQR) and mean ± SD SDI scores were 0 (0-1) and 0.62 ± 1.09. Compared with the non-neuropsychiatric SLE group, NPSLE patients were more likely to develop damage (adjusted (a)OR = 2.86; 95% CI = 2.28-3.59). This held true also after suppression of the NP SDI items (aOR = 1.70; 95% CI = 1.36-2.12). Beyond the neuropsychiatric domain, NPSLE was associated with damage in the cardiovascular (aOR = 2.63; 95% CI = 1.75-3.95), musculoskeletal (aOR = 1.90; 95% CI = 1.43-2.52), and skin (aOR = 1.54; 95% CI = 1.06-2.22) SDI domains. Dissecting domains into items, NPSLE was associated with coronary artery disease (aOR = 3.08; 95% CI = 1.44-6.58), myocardial infraction (aOR = 3.11; 95% CI = 1.54-6.27), muscle atrophy (aOR = 3.34; 2.16-5.16), scarring alopecia (aOR = 1.79; 95% CI = 1.19-2.70), bowel infarction (aOR = 1.98; 95% CI = 1.20-3.26), retinopathy (aOR = 2.23; 95% CI = 1.15-4.32), and premature gonadal failure (aOR = 2.10; 95% CI = 1.11-3.90).

conclusionThe intricate association between NPSLE and damage accrual extends beyond the nervous system to also comprise the musculoskeletal, skin, and cardiovascular organ systems.

Indexed as

Lupus Vasculitis, Central Nervous SystemAdultClinical Trials, Phase III as TopicFemaleHumansLogistic ModelsLupus Erythematosus, SystemicMaleMiddle AgedRandomized Controlled Trials as TopicRisk FactorsSeverity of Illness IndexNervous systemNeuropsychiatric lupusOutcomesSLICC/ACR damage indexSystemic lupus erythematosus

Identifiers

PMID39115551
PMCPMC11343782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.